Hantavirus pandemic in 2026?

The probability that a hantavirus pandemic will be declared in 2026 has fallen to 3.6 %, continuing a steady slide over the past month from 7.2 %. Over the most recent 24‑hour period the odds were unchanged, but the seven‑day decline of 2.4 percentage points coincided with the publication of a major vaccine development.

On June 12, researchers at the University of Texas Medical Branch published a study in *The Lancet* showing that a single‑dose vaccine provided full protection against the Andes hantavirus strain in animal testing. The Andes strain is the only hantavirus known to be capable of human‑to‑human transmission, making it the primary candidate for a pandemic scenario. The news appears to have reduced traders’ perception of near‑term outbreak risk, even though the vaccine has not yet entered human trials.

No other hantavirus‑specific news surfaced in the past 24 hours. Reports of Ebola spreading in DR Congo and a separate study on raccoon‑borne water contamination were not directly relevant to hantavirus risk, though they may have contributed to background pandemic chatter. However, the market’s 30‑day descent—from a high of about 7 % in mid‑May to the current 3.6 %—suggests that the absence of fresh hantavirus outbreaks, combined with the vaccine milestone, has gradually shifted trader sentiment toward lower probability.